The flow through cell methodology in the evaluation of intralumenal drug release characteristics

Dissolution Technologies

Volumn 12, Issue 2, 2005, Pages 17-21

  Fotaki, Nikoletta ^a   Reppas, Christos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; AMOXICILLIN; CARBAMAZEPINE; DANAZOL; ISOSORBIDE MONONITRATE; PARACETAMOL; TROGLITAZONE; VINCAMINE;

ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ARTICLE; DIGESTIVE TRACT PARAMETERS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG RELEASE; DRUG RELEASE TESTING; DRUG SOLUBILITY; EQUIPMENT DESIGN; EXTENDED RELEASE DOSAGE FORM; FLOATING DRUG DOSAGE FORM; FLOW RATE; FLOW THROUGH CELL APPARATUS; FOOD INTAKE; IMMEDIATE RELEASE DOSAGE FORM; IN VITRO IN VIVO CORRELATION; IN VITRO STUDY; INTRALUMINAL DRUG ADMINISTRATION; LIPOPHILICITY; ORAL DRUG DOSAGE FORM; PH; QUALITY CONTROL; SIMULATION;

EID: 84962050328     PISSN: 1521298X     EISSN: None     Source Type: Journal    
DOI: 10.14227/DT120205P17     Document Type: Article

References (44)

1. Vliet, E. B., Letter sent to the U. S. P. Subcommittee on Tablets (August 23), 1957.
2. Langenbucher, F., Benz, D., Kürth, W., Möller, H., Otz, M. Standardized flow-cell method as an alternative to existing pharmacopoeial dissolution testing. Pharm. Ind. 51, 1276-1281, 1989.
3. Rippie, E. G., Johnson, J. R. Regulation of dissolution rate by pellet geometry. J. Pharm. Sci. 51, 428-431, 1969.
4. Langenbucher, F. In vitro assessment of dissolution kinetics: description and evaluation of a column-type method. J. Pharm. Sci. 58 (10), 1265-1272, 1969.
5. Lerk, C. F., Zuurman, K. The influence of pulsation on the dissolution rate measurements in column type apparatus. J. Pharm. Pharmacol. 22 (4), 319-320, 1970.
6. Groves, M. J., Alkan M. H., Deer, M. A. The evaluation of a column-type dissolution apparatus. J. Pharm. Pharmacol. 27 (6), 400-407, 1975.
7. Langenbucher, F., Retting, H. Dissolution rate testing with the column method: methodology and results. Drug Dev. Ind. Pharm. 3 (3), 241-263, 1977.
8. USP 26-NF 21. The United States Pharmacopeia-The National Formulary. Rockville MD, 20852, The United States Pharmacopeial Convention, Inc., 2003.
9. Möller, H. Dissolution testing of different dosage forms using the flow through method. Pharm. Ind. 45, 617-622, 1983.
10. Bhattachar, S. N., Wesley, J. A., Fioritto, A., Martin, P. J., Babu, S. R. Dissolution testing of a poorly soluble compound using the flow through cell dissolution apparatus. Int. J. Pharm. 236, 135-143, 2002.
11. Sunesen, V. H., Vedelsdal, R., Kristensen, H. G., Christrup, L., Müllertz, A. Effect of liquid volume and food intake on the absolute bioavailability of a poorly soluble drug, danazol. Eur. J. Pharm. Sci. 24(4), 297-303, 2005.
12. Sunesen, V. H., Pedersen, B. L., Kristensen, H. G., Müllertz, A. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow through dissolution method with biorelevant dissolution media. Eur. J. Pharm. Sci., 24 (4), 305-13, 2005.
13. Moog, F. The lining of the small intestine. Scientific American, November issue, 116-125, 1981.
14. Ishii, K., Saito, Y., Itai, S., Takayama, K., Nagai, T. In vitro dissolution test corresponding to in vivo dissolution of sofalcone formulations. S. T. P. Pharma Sci. 7 (4), 270-276, 1997.
15. Nicolaides, E., Symillides, M., Dressman, J. B., Reppas, C. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm. Res. 18, 380-388, 2001.
16. Özdemir, N., Ordu, S., Özkan, Y. Studies of floating dosage forms of furosemide: in vitro and in vivo evaluations of bilayer tablet formulations. Drug Dev. Ind. Pharm. 26 (8), 857-866, 2000.
17. Fotaki, N., Vertzoni, M., Dressman, J. B., Reppas, C. Optimising the in vitro conditions to simulate the release process in stomach after meals, [6th European Congress of Pharmaceutical Sciences, Budapest], Eur. J. Pharm. Sci. (Suppl. 1) 11, S44, 2000.
18. Vertzoni, M., Iliadis, A., Nicolaides, E., Symillides, M., Reppas, C. Orally administered drug products: dissolution data analysis with a view to IVIVC, Chapter 8, Dressman JB and Kraemer J (Eds.), Taylor and Francis Books, (ISSN/ISBN 0-8247-5467-0), pp. 227-248, 2005.
19. Amidon, G. L., Lennernas, H., Shah, V. P., and Crison, J. R. A theoretical basis for a Biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res 12 (3), 413-420, 1995.
20. Kalantzi, L., Nicolaides, E., Page, R. C., Digenis, G. A., Reppas, C. Prediction of the average plasma profile after oral administration of cross-linked gelatin capsules of amoxicillin, Poster presentation, International Symposium on scientific and regulatory aspects of dissolution and bioequivalence, Athens, 2002.
21. Vertzoni, M., Dressman, J., Butler, J., Hempenstall, J., Reppas, C. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur. J. Pharm. Biopharm., in press, 2005.
22. Galia, E., Nicolaides, E., Hoerter, D., Loebenberg, R., Reppas, C., Dressman, J. B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 15, 698-705, 1998.
23. Digenis, G. A., Sandefer, E. P., Page, R. C., Doll, W. J., Gold, T. B., Darwazeh, N. B. Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture. Pharm. Res., 17(5) 572-582, 2000.
24. Kalantzi, L., Polentarutti, B., Albery, T., Laitmer, D., Abrahamsson, B., Dressman, J., Reppas, C. The delayed dissolution of paracetamol products in the canine fed stomach can be predicted in vitro but it does not affect the onset of plasma levels. Int. J. Pharm., 296(1-2), 87-93, 2005.
25. Macheras, P., Koupparis, M., Tsaprounis, C. Drug dissolution studies in milk using the automated flow injection serial dynamic dialysis technique. Int. J. Pharm. 33, 125-136, 1986.
26. Kelly, K., O'Mahony, B., Lindsay, B., Jones, T., Grattan, T., Rostami-Hodjegan, A., Stevens, H. N. E., Wilson, C. G. Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using g-scintigraphy. Pharm. Res. 20, 1668-1673, 2003.
27. Bonlokke, L., Hovgaard, L., Kristensen, H. G., Knutson, L., Lennernas, H. Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans. Eur J Pharm Sci. 12 (3), 239-50, 2001.
28. Nicolaides, E., Hempenstall, J. M., Reppas, C. Biorelevant dissolution tests with the flow through apparatus? Dissolution Technologies 7 (1), 8-11, 2000.
29. Bonlokke, L., Hovgaard, L., Kristensen, H. G., Knutson, L., Lindahl, A., Lennernas, H. A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans. Eur J Pharm Sci. 8 (1), 19-27, 1999.
30. Dressman, J. B., Amidon, G. L., Reppas, C., Shah, V. P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15, 11-22, 1998.
31. Möller, H., Langenbucher, F. In vitro and in vivo dissolution of some sustained release tablets of theophylline. Pharm. Ind. 44 (10), 1065-1071, 1982.
32. Emara, L. H., El-Menshawi, B. S., Estefan, M. Y. In vitro-in vivo correlation and comparative bioavailability of vincamine in prolonged-release preparations. Drug Dev. Ind. Pharm. 26 (3), 243-251, 2000.
33. Fotaki, N., Symillides, M., Reppas, C. In vitro vs. canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis. Eur. J. Pharm. Sci., 24, 115-122, 2005.
34. Randall, J. M. The colon as a site for drug delivery. J. Control. Release 22, 15-34, 1992.
35. Ashford, M., Fell, J., Attwood, D., Woodhead, P. J. An in vitro investigation into the suitability of pH-dependent polymers for colonic targeting. Int. J. Pharm. 91, 241-245, 1993.
36. Ashford, M., Fell, J. Targeting drugs to the colon: delivery systems for oral administration. J. Drug Target. 2 (3), 241-257, 1994.
37. Rodriguez, M., Vila-Jato, J. L., Torres, D. Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. J. Control. Release 55 (1), 67-77, 1998.
38. Cole, E., Scott, R., Connor, A., Wilding, I, Petereit, H. U., Schminke, C., Beckert, T., Cade, D. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int. J. Pharm. 231, 83-95, 2002.
39. Elkington, S. G. Lactulose. Gut 11, 1043-1048, 1970.
40. Gruber, P., Longer, M. A., Robinson, J. R. Some biological aspects in oral, controlled drug delivery. Adv. Drug Deliv. Rev. 1, 1-18, 1987.
41. Evans, D. F., Pye, G., Bramley, R., Clark, A. G., Dyson, T. J., Hardcastle, J. D. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 29, 1035-1041, 1988.
42. Macfarlane, G. T., Cummings, JH. The colonic flora, fermentation, and large bowel digestive function. In: Phillips, S. F., Pemberton, J. H., Shorter R. G. (Eds.), The Large Intestine: Physiology, Pathophysiology, and Disease, chapter 4, Mayo Foundation, Raven Press, New York, pp. 51-92, 1991.
43. Press, A. G., Hauptmann, I. A., Hauptmann, L., Fuchs, B., Fuchs, M., Ewe, K., Ramadori, G. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 12, 673-678, 1998.
44. Nugent, S. G., Kumar, D., Rampton, D. S., Evans, D. F. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 48 (4), 571-577, 2001.